Moffitt logo
    Search

    Choose a type to search within:

    All Doctors Clinical Trials Researchers
    search icon
    • Schedule
      New Patients
       
      Referring Physicians
    • Locations
      Magnolia
       
      McKinley
       
      Wesley Chapel
       
      International Plaza
       
      Moffitt at Memorial
       
      Fowler
       
      Telecomm/Intellicenter
    • Find a Doctor
    • MyMoffitt Portal
      Log In
       
      Enroll
    • Donate
    • 1-888-663-3488
    • image Search
    • Cancer Types & Treatments
        Cancers We Treat
      • Adrenal
      • Anal
      • Appendiceal (Appendix)
      • Astrocytoma
      • Basal Cell Carcinoma
      • Bladder
      • Bone Metastasis
      • Brain
      • Brain Tumor
      • Breast
      • Cervical
      • Cholangiocarcinoma (Bile Duct )
      • Colon
      • Colorectal
      • Cutaneous T-Cell Lymphoma
      • Ductal Carcinoma In Situ
      • Endometrial (Uterine)
      • Esophageal
      • Gallbladder
      • Gastrointestinal Carcinoid Tumor
      • GIST (Gastrointestinal Stromal Tumor)
      • Glioblastoma
      • Head and Neck
      • HER2 Positive Breast
      • Hodgkin Lymphoma
      • Inflammatory Breast
      • Invasive Ductal Carcinoma
      • Kidney (Renal Cell)
      • Leukemia
      • Liver (Hepatocellular)
      • Lung
      • Lymphomas (Hodgkin and Non-Hodgkin)
      • Melanoma
      • Meningioma
      • Merkel Cell Carcinoma
      • Mesothelioma
      • Metastatic Breast
      • Multiple Myeloma-Plasma Cell Tumor
      • Myelodysplastic Syndromes (MDS)
      • Neuroendocrine Tumor
      • Neurofibromatosis
      • Non-Hodgkin Lymphoma
      • Oral Cavity (Mouth)
      • Oral Cavity or Throat
      • Osteosarcoma
      • Ovarian
      • Pancoast Tumor
      • Pancreatic
      • Penile
      • Pituitary Adenoma
      • Prostate
      • Rectal
      • Sarcoma
      • Skin (Nonmelanoma)
      • Skull Base Tumors
      • Small Intestine
      • Spinal Tumor
      • Squamous Cell Carcinoma
      • Stomach (Gastric)
      • Testicular
      • Throat
      • Thymoma
      • Thyroid
      • Tongue
      • Tracheal
      • Triple Negative Breast
      • Vaginal
      • Vulvar
        Cancer Diagnostics and Treatments
      • Blood & Bone Marrow Transplant
      • Cardio-Oncology
      • Chemotherapy
      • Clinical Pathways
      • Clinical Trials
      • Endoscopic Procedures
      • Fertility Preservation
      • Gynecologic Oncology
      • Immunotherapy
      • Interventional Pain Management
      • Interventional Radiology
      • Personalized Medicine
      • Pharmacy
      • Radiation Therapy
      • Rehabilitation Services
      • Supportive Care Medicine
      • Surgical Care
      • Systemic Therapy
      • Targeted Therapy
      • Tumor Board
        Diagnostic Services
      • Radiology – Diagnostic Imaging and Interventional Radiology
      • Genetic Counseling and Genetic Testing
      • Pathology
      • Labwork and Bloodwork
      • Cancer Screenings
    • Patients & Families
        Patients and Families Resources Overview
      • International Referral Services
      • Moffitt Virtual Visits
      • Taking Care of Your Health
        Preparing For Your Appointment
      • Scheduling Your Appointment
      • MyMoffitt Patient Portal
      • Patient and Family Orientation
      • Patient Rights and Responsibilities
      • Medical Records
      • Traveling for Cancer Treatment
        Insurance & Financial Information
      • Insurance Coverage
      • Health Exchange
      • Medicare Coverage
      • Copay Assistance Program
      • Financial Assistance
      • Financial Information
      • Obtain a Cost Estimate
      • Understanding Your Bill
      • Frequently Asked Questions
        Programs & Support Services
        Patient and Family-Centered Care
        Cancer Survivorship
        Caregivers and Families
    • For Healthcare Professionals
        For Healthcare Professionals Overview
      • Clinical Perspectives
        Programs & Services
      • Adolescent & Young Adult (AYA)
      • Anesthesiology
      • BMT and Cellular Immunotherapy
      • Breast Oncology
      • Cardio-Oncology
      • Cutaneous Oncology
      • Diagnostic Imaging and Interventional Radiology
      • Endocrine Oncology
      • Gastrointestinal Oncology
      • Genetic Counseling
      • Genitourinary Oncology
      • Gynecologic Oncology
      • Head and Neck Oncology
      • Immunotherapy
      • Malignant Hematology
      • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
      • Neuro-Oncology
      • Pathology
      • Pharmacy
      • Radiation Oncology
      • Sarcoma
      • Screening & Prevention
      • Senior Adult Oncology
      • Supportive Care Medicine
      • Thoracic Oncology
        Physician Relations
        Continuing Education
      • Provider Conferences
      • Moffitt Grand Rounds
      • Multidisciplinary Programs
    • Research
        Research Overview
        CCSG Programs
      • Cancer Biology and Evolution
      • Cancer Epidemiology
      • Health Outcomes & Behavior
      • Immuno-Oncology
      • Molecular Medicine
        Divisions and Departments
      • Biostatistics and Bioinformatics
      • Cancer Epidemiology
      • Drug Discovery
      • Health Outcomes and Behavior
      • Immunology
      • Integrated Mathematical Oncology
      • Machine Learning
      • Metabolism and Physiology
      • Molecular Oncology
      • Tumor Biology
        Centers and Institutes
      • Institutes
      • Centers of Excellence
        Shared Resources
      • Analytic Microscopy
      • Biostatistics and Bioinformatics
      • Cancer Pharmacokinetics and Pharmacodynamics
      • Cell Therapies
      • Chemical Biology
      • Collaborative Data Services
      • Flow Cytometry
      • Gene Targeting
      • Molecular Genomics
      • Participant Research, Interventions, and Measurement Core (PRISM)
      • Proteomics and Metabolomics
      • Quantitative Imaging Core
      • Small Animal Imaging Lab
      • Tissue
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
        Community Outreach, Engagement, and Equity
      • About Us
      • Catchment Area Cancer Data
      • Moffitt Outreach in the Community
      • Research in the Community
      • Education and Outreach Resources
      • Get Involved
        Innovation and Industry Alliances
      • Available Technologies
      • Business of Biotech
      • Events
      • Internship Programs
      • Technology And Innovation Fund
      • Contact Us
    • Training & Education
        Training and Education Overview
      • Moffitt Innovators of Tomorrow Symposium
        Medical Education
      • Program Staff/Contact Us
      • Our Training Programs
      • Salary and Benefits
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
      • Where Are They Now
        Nursing Education
      • Oncology Nurse Residency Program
      • Ambulatory Care Oncology Nurse Residency Program
      • Registered Nurse
      • Nurse Anesthetist
      • Nurse Practitioner
        Health Professional Education
        Continuing Education
        Other Educational Programs
    • Give
        Give Overview
        Ways to Give
      • Cash, Stock or Other Assets
      • Planned Giving
      • Philanthropic Foundation Giving
      • Corporate Partnership
      • Employer Matching Gifts
      • Endowment Gifts
      • Other Ways to Donate
        Get Involved
      • Become a Member
      • Join a Community Partner Event
      • Volunteer Your Time
      • Miles for Moffitt
      • Magnolia
      • Mission Possible Sarasota Luncheon
      • Discovery Series Webinars
        Why Give?
      • About the Moffitt Foundation
      • FAQ
      • Financials and Stewardship
      • Contact the Foundation
      • You Can Make a Difference
      • 2021 Annual Foundation Impact Report
    1. Home
    2. Newsroom
    3. Press Release Archive
    4. 2016
    5. Moffitt Researchers Develop a Novel Cancer Treatment Approach Based on Evolutionary Principals to Inhibit Chemo-Resistance, Prolong Progression-Free Survival
    • click to share
      Facebook
      Twitter
      Linkedin
      Pinterest
      Email
    • click to print

    Moffitt Researchers Develop a Novel Cancer Treatment Approach Based on Evolutionary Principals to Inhibit Chemo-Resistance, Prolong Progression-Free Survival

    February 24, 2016

    TAMPA, Fla. – Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.

    The standard strategy for administering cancer chemotherapy has changed very little over the past five decades.  Cancer drug are typically given at the maximum tolerated dose that a patient can tolerate without any life-threatening toxicity.  While this strategy works very effectively at killing cancer cells in the short-term, once the chemo-sensitive cells are removed, existing chemo-resistant cells survive and then continue to grow and divide despite the ongoing therapy.

    Previously, Moffitt researchers developed a novel treatment strategy based on evolutionary principals and tested originally through mathematical models.  Rather than reducing tumor size with a maximum tolerated dose and leaving only resistant cells, the researchers’ goal was to prolong survival without disease progression.  This strategy, termed an adaptive strategy, uses short bursts of therapy to maintain a residual population of chemo-sensitive cells that keep resistant cells in check and prevent them from growing uncontrollably.

    According to Robert Gatenby, M.D., study author and leader of the Cancer Biology & Evolution Program at Moffitt, “there is a natural tendency to use high-dose therapy based on the assumption that each patient receives maximum benefit by killing as many cancer cells as possible. However,  according to evolutionary principals, high-dose therapy is the least likely to be successful in controlling  the tumor for any length of time because it intensely selects for resistant cells and allows them to grow rapidly because the treatment has eliminated all of their competitors. It is hard to get people to think of an alternative approach in which less therapy might actually be more effective over time. We want to try to work with evolution rather than letting evolution be a source of our defeat.”

    A new article by Gatenby and colleagues published in the Feb. 24 issue of the journal Science Translational Medicine reports that adaptive therapy is effective in preclinical mouse models of triple-negative and ER+ breast cancer.  They treated mice with the common breast cancer chemotherapeutic agent paclitaxel according to three different treatment strategies: the standard maximum dose (ST), an adaptive therapeutic dose (AT-1) in which the frequency of paclitaxel is the same but the dose decreases as the tumor responds, and a second adaptive therapeutic dose (AT-2) in which the dose of paclitaxel is the same but doses are skipped when the tumor responds to therapy.

    The researchers found that all three treatment strategies initially decreased tumor growth to similar levels; however, as soon as the tumors responded and treatment stopped during the standard regimen or was skipped during the AT-2 regimen, the tumors rapidly regrew.  Alternatively, treatment with the AT-1 dosing regimen resulted in a long-term stabilization of the tumor to the point that lower doses of paclitaxel could be used and eventually treatment was able to be withdrawn completely. Mice treated with the AT-1 regimen survived significantly longer than the mice in the standard and AT-2 treatment groups.

    The study showed that adaptive treatment with the AT-1 regimen increases vessel density and blood flow throughout the tumor.  This allows chemotherapeutic drugs to be delivered to the tumor more effectively and reduces tumor cell invasion. 

    Based on these promising preclinical results, Moffitt researchers, led by Jingsong Zhang, M.D., Ph.D., assistant member of the Genitourinary Oncology Program, have initiated the first clinical trial assessing the efficacy of an adaptive treatment strategy in prostate cancer patients.  Abiraterone is an inhibitor of androgen synthesis and is typically given to relapsed prostate cancer patients at the maximum tolerated dose. The research team wants to assess if adaptive therapy with abiraterone extends progression-free survival, particularly in African-American men who tend to develop resistance to hormone therapy more rapidly and have a poorer prognosis than other ethnic groups.

    A computerized model will be created for each patient to allow individualized treatment based on response to therapy. Patients’ PSA levels will be monitored throughout the study and treatment with abiraterone will be stopped and only re-initiated if there is a 50 percent of more increase in the level of PSA.

    Gatenby emphasized that “evolving populations can only adapt to the here and now, they can never anticipate the future. But scientists and oncologists can anticipate the future because we understand evolution. Our understanding of evolution is what allows us to develop therapies that could be successfully used in the clinic.”

    Individuals interested in finding out more information about the ongoing prostate cancer trial with abiraterone adaptive therapy should contact Cortlin Croft at 813-745-7559 or Jesse Mocha at 813-745-2629.

    The preclinical research was supported by funds received from the James S. McDonnell Foundation, the National Institutes of Health (R01CA170595, U54CA143970-05), and the Analytic Microscopy Core Facility at Moffitt, an NCI-designated Comprehensive Cancer Center (P30-CA076292).

    About Moffitt Cancer Center

    Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. One of the three largest cancer centers in the United States based on patient volume, the Tampa-based facility is one of only 45 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in Florida and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer care since 1999. Moffitt devotes more than 2 million square feet to research and patient care. With more than 5,000 team members, Moffitt has an economic impact in the state of $1.9 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.

     

    ###

    Twitter

    Tweets by MoffittNews
    footer logo
    • BROWSE
      • Cancer Types & Treatments
      • Careers
      • Clinical Trials
      • Diagnostic Services
      • Education & Training
      • Locations
      • Patients & Families
      • Research
    • ABOUT
      • About Moffitt
      • Available Technologies
      • Calendar of Events
      • Clinical Perspectives
      • Community Benefit
      • Diversity
      • Endeavor
      • Newsroom
      • Our Outcomes
      • Partnerships
      • Taking Care of Your Health
    • ACTION
      • Appointments
      • Find a Doctor
      • Patient Portal
      • Refer a Patient
      • Referring Provider Portal
      • Staff Login
      • Staff Access
      • Volunteer
      • Ways to Give
    Call Today 1-888-663-3488
    Link to FaceBook
    Facebook
    Link to Twitter
    Twitter
    Link to Instagram
    Instagram
    Link to YouTube
    YouTube
    nci designated comprehensive cancer center award
    nccn award
    magnet recognized award
    diversity inc award
    • Site Map
    • Privacy Policy
    • Terms & Conditions
    • Unsubscribe
    • State Nonprofit Disclosures
    • Donor Privacy
    • Notice of Privacy Practices
    • Visitor Policy
    ©Copyright 2023 Moffitt Cancer Center
    ✕

    Request an Appointment at Moffitt Cancer Center

    Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.

    NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.

    REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.

    Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.


    Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub

    ✕

    Access Your Portal

    For Patients

    A secure website for patients to access their medical care at Moffitt.

    PATIENT PORTAL LOGIN

    For Physicians

    An online resource for referring physicians and their staff.

    PROVIDER PORTAL LOGIN

    For Moffitt Staff

    For Moffitt faculty & staff members to access MoffittNet applications.

    STAFF PORTAL LOGIN

    ✕

    Call: 1-888-663-3488

    Call: 1-888-663-3488

    Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.

    Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday